Sign up to save your podcasts
Or
Share ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASH Lymphoma 2024 Highlights - POLARIX Update, inMIND, TRIANGLE, ENRICH with Dr. Pallawi Torka
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.
In this episode, we dive into:
• POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
• inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
• Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
• ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.
Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast
View all episodes
By Oncology Brothers
4.8
3636 ratings
Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma.
In this episode, we dive into:
• POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS).
• inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma.
• Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment.
• ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy.
Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice!
#OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Breast Cancer Update
62 Listeners
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
110 Listeners
The NPR Politics Podcast
25,760 Listeners
ASCO Daily News
55 Listeners
The Curbsiders Internal Medicine Podcast
3,318 Listeners
Core IM | Internal Medicine Podcast
1,084 Listeners
OncoPharm
183 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
The Clinical Problem Solvers
513 Listeners
Run the List
245 Listeners
Oncology Today with Dr Neil Love
55 Listeners
Two Onc Docs
165 Listeners
Blood Cancer Talks
49 Listeners